Drug interventions for prevention of COVID-19 progression to severe disease in outpatients: a systematic review with meta-analyses and trial sequential analyses (The LIVING Project).

ABSTRACT:

Objectives

To assess the effects of interventions authorised by the European Medicines Agency (EMA) or the US Food and Drug Administration (FDA) for prevention of COVID-19 progression to severe disease in outpatients.

Setting

Outpatient treatment.

Participants

Participants with a diagnosis of COVID-19 and the associated SARS-CoV-2 virus irrespective of age, sex and comorbidities.

Interventions

Drug interventions authorised by EMA or FDA.

Primary outcome measures

Primary outcomes were all-cause mortality and serious adverse events.

Results

We included 17 clinical trials randomising 16 257 participants to 8 different interventions authorised by EMA or FDA. 15/17 of the included trials (88.2%) were assessed at high risk of bias. Only molnupiravir and

SUBMITTER: Petersen JJ 

PROVIDER: S-EPMC10314423 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature